1700 Owens Street
About Nurix Therapeutics
Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels.
Nurix’s wholly owned pipeline comprises targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California.
25 articles with Nurix Therapeutics
Here’s a run-down of some of the most recent collaboration announcements this week.
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur Sands, M.D., Ph.D., Nurix’s chief executive officer, will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 3:40 p.m. EST. The presentation will be webcast live and may be accessed via a link in the Investors section of the Nurix website
Nurix Therapeutics Presents Preclinical Data at 62nd American Society of Hematology (ASH) Annual Meeting and ExpositionData support a planned clinical trial of NX-2127 in B-cell malignancies
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the presentation of key preclinical data from its lead program, NX-2127, for the potential treatment of B-cell malignancies, at the 62 nd American Society of Hematology (ASH) Annual Meeting and Exposition. Supported by these data, Nurix plans to initiate a Phase 1 clinical trial of orally administered NX-2127 in
Nurix Therapeutics, Inc., a biopharmaceutical company developing targeted protein modulation drugs, announced that it will be presenting at the following healthcare investor conferences
Nurix Therapeutics Announces Appointment of Robert Tjian as Chairman of Scientific Advisory Board and His Resignation from the Board of Directors
Nurix Therapeutics, Inc. (Nasdaq: NRIX), today announced that, based on his desire to lead Nurix’s Scientific Advisory Board, Robert Tjian, Ph.D. has resigned from the Company’s Board of Directors effective November 1, 2020
Nurix Therapeutics Reports Third Quarter Fiscal 2020 Financial Results and Provides a Corporate Update
Nurix Therapeutics Inc. (Nasdaq: NRIX), a biotechnology company developing targeted protein modulation drugs, today reported financial results for the third quarter ended August 31, 2020 and provided a corporate update. Recent Business Highlights Strengthened Leadership Team with Key Appointments . Added Dr. Mich
Nurix Therapeutics, Inc., (NASDAQ: NRIX), a company developing targeted protein modulation drugs, today announced the Company will be presenting at the 3rd Targeted Protein Degradation (TPD) Summit held virtually.
Nurix Therapeutics, Inc. (Nurix), a company developing targeted protein modulation drugs, today announced the pricing of its initial public offering of 11,000,000 shares of its common stock at a price to the public of $19.00 per share. All of the shares are being offered by Nurix. The shares are expected to begin trading on The Nasdaq Global Market on July 24, 2020 under the symbol “NRIX.” The gross proceeds from the offering, before deducting u
Nurix Therapeutics, Inc., a company developing targeted protein modulation drugs, today announced the appointment of Dr. Michael T. Lotze as chief cellular therapy officer (CCO) and Dr. Robert J. Brown as vice president of clinical development.
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
It expects to use the funds to advance its wholly-owned development candidates into the clinic.
Nurix Therapeutics and Sanofi Establish Strategic Collaboration to Develop Novel Targeted Protein Degradation Therapies
Nurix will utilize its proprietary drug discovery platform, DELigase™, that integrates its DNA-encoded libraries and its unparalleled portfolio of E3 ligases to create small molecules designed to induce degradation of three specified drug targets, with an option by Sanofi to expand to a total of five targets.
How do you catch just one kind of fish in a sea of similar fish? That’s the question being answered by researchers at Nurix, except they aren’t catching fish – they are ‘catching’ proteins in your body.
10/11/2019Companies strengthen their leadership teams and boards of directors with these appointments.
Gilead and Nurix Establish Strategic Collaboration to Develop Novel Therapies for Cancer and Other Diseases
Collaboration will Leverage Nurix’s Proprietary Drug Discovery Platform to Identify Novel Agents that Induce Degradation of Specified Drug Targets
The focus will be on discovering drugs that use the body’s natural protein control processes.